Eli Lilly and Company is a global pharmaceutical manufacturer that discovers, develops, and markets human medicines across cardiometabolic, oncology, immunology, and neuroscience therapeutic areas, serving healthcare systems and patients in approximately 90 countries. The company generates revenue primarily through distribution via major U.S. wholesalers, direct sales to healthcare providers, and increasingly through direct-to-patient channels, while competing against branded, biosimilar, and generic alternatives. Success depends on continuous innovation, strong intellectual property protections that extend market exclusivity, and navigating complex regulatory requirements worldwide, though the company faces ongoing margin pressures from government price controls, payer formulary negotiations, and biosimilar competition as patents expire on key products.